New hope for scleroderma patients with worsening lung disease?
NCT ID NCT01570764
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tested whether adding a strong immune-suppressing drug (cyclophosphamide) to standard steroid treatment (prednisone) could stop or slow lung damage in people with scleroderma-related lung disease. 40 adults with worsening lung function took part. The goal was to see if more patients could stabilize or improve their lung capacity after 12 months compared to those on placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.